Aadi Bioscience (NASDAQ:AADI - Get Free Report) posted its quarterly earnings data on Tuesday. The company reported ($0.67) EPS for the quarter, missing analysts' consensus estimates of ($0.30) by ($0.37), Zacks reports. The firm had revenue of $7.24 million during the quarter, compared to the consensus estimate of $7.45 million. Aadi Bioscience had a negative return on equity of 71.87% and a negative net margin of 246.06%.
Aadi Bioscience Trading Up 4.6 %
Shares of NASDAQ AADI traded up $0.09 during mid-day trading on Friday, reaching $2.05. The company had a trading volume of 401,616 shares, compared to its average volume of 245,295. The stock has a market cap of $50.63 million, a PE ratio of -0.90 and a beta of 0.68. The company has a 50-day moving average price of $2.60 and a two-hundred day moving average price of $2.40. Aadi Bioscience has a 1-year low of $1.21 and a 1-year high of $3.81.
About Aadi Bioscience
(
Get Free Report)
Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.
Read More
Before you consider Aadi Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.
While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market volatility creates opportunity. Our analysts have pinpointed 10 stocks perfectly positioned for exceptional growth this spring, even amid economic uncertainty. Don't miss your chance to access this timely research and invest with confidence.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
